Lantern Pharma up after positive data on brain cancer drug candidate

Lantern Pharma

22/11/2022 15:42

** Shares of biopharma co Lantern Pharma Inc  LTRN.O  rise
5% to $5.3 
    ** Co reports positive preclinical data on drug candidate
LP-184's efficacy in treating one of the most aggressive types
of brain cancer, glioblastoma (GBM)
    ** LP-184 tested alone and in combination with U.S. FDA
approved drug spironolactone observed anti-tumor effect - Co
    ** Spironolactone is mainly used in the treatment of heart
failure and high blood pressure
    ** Positive data on LP-184 accelerates targeted
Investigational New Drug (IND) application submission to FDA in
Q1 2023, with early stage trial in humans anticipated to
commence in Q2 2023 - LTRN
    ** Including session's gain, stock down 33.7% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))